Exercise, Neuronal Plasticity, Schizophrenia
Conditions
Brief summary
Aerobic endurance training has shown positive effects on symptoms, cognition, daily functioning, and the structure of the hippocampus in patients with schizophrenia. The study investigates genetic and epigenetic influences on neuroplastic changes following three months of endurance training. A control group performs flexibility, strength, and balance training. The main objective is to examine the association between a genetic risk score for schizophrenia and volume increase in the CA4/DG region of the hippocampus. Additional goals include examining changes in synapses, brain structure, function, and metabolism, as well as clinical symptoms and cognitive performance.
Interventions
PROCEDUREAerobic Endurance Training
Aerobic endurance training on a bicycle ergometer (week 1 to 6: three units per week á 40 minutes, week 7 to 12: three units á 45 minutes, in groups of up to three patients over 13 weeks)
PROCEDUREFlexibility, strengthening and balance training
Flexibility, strengthening and balance training (exercises from the areas of stretching, strength, balance and relaxation, 3x40 min from week 1-2, 3x45 min from week 3-4 and 3x50 min from week 5-13, in groups of up to three patients over 13 weeks)
Sponsors
German Research Foundation
LMU Klinikum
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent for voluntary study participation. * Patients with schizophrenia: diagnosis of schizophrenic psychosis according to ICD10 and DSM V, * Positive And Negative Syndrome Scale (PANSS) total score ≤ 75 before the start of the intervention * Reliable contraception in women of childbearing age * Patients must have been treated with individualized medication according to valid treatment guidelines. All antipsychotic substances are allowed, also as depot medication. Treatment with one as well as with two antipsychotic substances is possible. The additional administration of low- and medium-potency antipsychotic substances as on-demand medication for the treatment of agitation and sleep disorders is possible, provided that the daily dosage of 150 CPZ units is not exceeded. The active substance and dose of the individualized antipsychotic medication used to achieve the inclusion criterion of psychopathological symptom remission must be constant for at least 2 weeks before inclusion in the study.
Exclusion criteria
* Lack of reliability and sanity (examined by an independent psychiatrist) * Positive urine drug screen for illicit drugs (except benzodiazepines) * Acute suicide risk * Other relevant psychiatric axis-I disorders according to the diagnostic testing procedure (Mini International Neuropsychiatric Interview, MINI) * Other relevant neurological or other disorders * Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hippocampal volume | 13 weeks | Change in hippocampal subregion cornu ammonis (CA) 4 volume (∆CA4/DG) and its correlation with polygenetic risk factor (PRS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular risk factors | 13 weeks | Aerobic fitness levels (W/kg), body weight, waist circumference, body fat, lipid panel, HbA1c, physical activity as assessed with the IPAQ will be evaluated. |
| Executive functions | 13 weeks | visual attention and task switching (TMT-A, B), episodic memory with the What-Where-When Test and visuo-spatial short- and long-term memory with the Brief Visuospatial Memory Test-Revised (BVMT-R) |
| Symptoms severity | 13 weeks | change over study duration assessed by PANSS, BNSS, CDSS |
| Functioning in daily life | 13 weeks | Assessed by SOFAS, GAF, FROGS |
| Cognitive functions | 13 weeks | verbal memory, working memory, motor speed, verbal fluency, attention and speed of information processing assessed by BACS |
Countries
Germany
Contacts
Primary ContactIsabel Maurus, Dr.
Backup ContactLukas Roell, M.Sc.
Outcome results
None listed